Updated on 4 September 2025
Novel Platinum-Based Drug (HJ-550 )
About
A first-in-class targeted bivalent platinum drug exhibits overall superior efficacy over first-line standard-of-care treatments as monotherapy and in combination, holding potential to transform first-line tumor therapeutic strategies.
Project Location
- China
Project Format
- Private Project
ESG (Environmental, Social, and Governance)
- Yes
Project Stage
- Feasibility Study Completed
Main Project Sector
- Technology
Technology
- Bio-Tech
Interested Format of Cooperation
- Joint Venture
- Minority Shareholdings
- Open for Negotiation
- R&D Cooperation
Preferred Financing Model
- Equity
Previous Funding Stage
- Seed & Pre-Series
Main Service(s) Required
- Financial Services
- Professional Services
Financial Services
- Investment Banking
- Private Equity & Venture Capital
Professional Services
- Business Valuation
- Corporate Services
- Legal Advisory
Attached files
Organisation
Shanghai Haiju Biotechnology Co., Ltd.
Shanghai, China
Similar opportunities
Project
Novel MET Amplification-Targeting Small-Molecule Kinase Inhibitor (HJ-462 BIC)
- Yes
- Equity
- Bio-Tech
- Technology
- Joint Venture
- Private Project
- R&D Cooperation
- Seed & Pre-Series
- Financial Services
- Business Valuation
- Corporate Services
- Open for Negotiation
- Open for negotiation
- Professional Services
- Minority Shareholdings
- Institutional Investment
- Feasibility Study Completed
- Market Entry Strategic Analysis
- Private Equity & Venture Capital
Haiyang Wang
CEO at Shanghai Haiju Biotechnology Co., Ltd.
Shanghai, China
Project
Single Cell Drug Screening AI Platform
- Yes
- None
- Equity
- Bio-Tech
- Technology
- Private Project
- R&D Cooperation
- Open for negotiation
- Professional Services
- Minority Shareholdings
- 2,500,001 to 5,000,000 USD
- 1,000,001 to 2,500,000 USD
- Feasibility Study Completed
- Public–private partnership / Concession
Marco Suen
Founder & CEO at Provectus Therapeutics Limited
Hong Kong, China (Hong Kong)
Project
- No
- None
- Equity
- Fin-Tech
- Technology
- Private Project
- Big Data Solution
- Financial Services
- Industry Solutions
- Corporate Services
- Open for Negotiation
- Open for negotiation
- Enterprise Solutions
- Minority Shareholdings
- Corporate Intelligence
- Requisition of Service
- 500,001 to 1,000,000 USD
- Feasibility Study Completed
- Private Equity & Venture Capital
Yuan Wang
生态合伙人 at WarrenT AI
深圳, China